PMID: 8610914May 15, 1996Paper

Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial

Annals of Internal Medicine
M RobinsonM Haber

Abstract

To compare the efficacy of two doses of lansoprazole with that of placebo in preventing recurrence of erosive esophagitis in a 12-month period. Randomized, double-blind, parallel, placebo-controlled trial. 25 U.S. medical centers. 173 patients with documented healing of erosive esophagitis after 8 weeks of acid-suppressing therapy. Lansoprazole, 15 mg or 30 mg, or placebo once daily for as long as 12 months. Endoscopy and symptom evaluation after 1, 2, 3, 6, 9, and 12 months of treatment. Endoscopy was also done whenever symptoms suggested erosive changes. Lansoprazole was significantly superior to placebo in maintaining healing and preventing recurrence of symptoms. By month 1, 45% of placebo recipients remained healed compared with more than 90% of patients in either lansoprazole group. By month 12, only 24% of placebo recipients remained healed compared with 79% of patients receiving 15 mg of lansoprazole and 90% of patients receiving 30 mg of lansoprazole. During the same period, 35% of placebo recipients remained asymptomatic compared with 72% of recipients of 15 mg of lansoprazole and 67% of recipients of 30 mg of lansoprazole. The 15-mg and 30-mg lansoprazole doses did not differ significantly in maintaining healing and ...Continue Reading

Citations

May 16, 2006·Journal of Gastroenterology·Yuji NaitoToshikazu Yoshikawa
Jul 12, 2002·The Urologic Clinics of North America·Mark A Moyad
Mar 1, 2000·Gastroenterology Clinics of North America·K R DeVault
Jun 26, 1999·Alimentary Pharmacology & Therapeutics·J E RichterR Fisher
Sep 1, 1999·Alimentary Pharmacology & Therapeutics·A SonnenbergL A Becker
Nov 26, 1999·Alimentary Pharmacology & Therapeutics·J EscourrouC Maier
Oct 31, 2001·Alimentary Pharmacology & Therapeutics·K GeboesUNKNOWN Dutch Study Group
Mar 1, 1997·Journal of Clinical Gastroenterology·K G TolmanG L Ringham
Jul 13, 2002·American Journal of Therapeutics·Alberto PilottoGianni Valerio
Feb 14, 2007·Journal of Gastroenterology and Hepatology·Masashi KawamuraToru Shimosegawa
Jul 21, 2000·The Western Journal of Medicine·D A Katzka
Mar 10, 2009·Digestive Diseases and Sciences·Thomas O KovacsDavid A Peura
Aug 30, 2008·Digestive Diseases and Sciences·David A PeuraStuart Atkinson
Jan 20, 2010·Journal of Forensic and Legal Medicine·J J Payne-JamesT C B Moore
Sep 27, 2000·Baillière's Best Practice & Research. Clinical Gastroenterology·P J Kahrilas
Jul 4, 2002·The American Journal of Gastroenterology·F BaldiUNKNOWN Italian Lansoprazole Study Group
Jan 13, 2001·Mayo Clinic Proceedings·A S Arora, D O Castell
Oct 4, 2005·European Journal of Internal Medicine·Doron Zamir
Nov 12, 2002·The American Journal of Gastroenterology·Robert D ThomsonNora R Ratcliffe
Feb 5, 2002·Expert Opinion on Pharmacotherapy·D A Gremse
May 7, 2009·Alimentary Pharmacology & Therapeutics·J W FrestonB Hunt
May 16, 2002·Drugs·James W FrestonE David Ballard
Dec 14, 2006·Expert Opinion on Pharmacotherapy·Dawn D Ferguson, Kenneth R DeVault
Aug 9, 2008·American Journal of Physiology. Gastrointestinal and Liver Physiology·Claudia P SanmiguelEdy E Soffer
Feb 19, 2010·The Cochrane Database of Systematic Reviews·Clare DonnellanNav Sharma
Aug 30, 2013·Expert Review of Gastroenterology & Hepatology·Anthony O'Connor, Colm O'Moráin
Jan 31, 2004·Scandinavian Journal of Gastroenterology·M Bortolotti
Mar 16, 2000·Journal of General Internal Medicine·G R HeudebertC M Wilcox
Nov 1, 1996·Postgraduate Medicine·W M Brady, C P Ogorek

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.